- Home
- LFWD vs NXTC Comparison
LFWD vs NXTC Comparison
Compare LFWD & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LFWD
- NXTC
- Stock Information
- Founded
- LFWD 2001
- NXTC 2015
- Country
- LFWD Israel
- NXTC United States
- Employees
- LFWD N/A
- NXTC N/A
- Industry
- LFWD
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- LFWD
- NXTC Health Care
- Exchange
- LFWD NYSE
- NXTC Nasdaq
- Market Cap
- LFWD 11.8M
- NXTC 13.9M
- IPO Year
- LFWD 2014
- NXTC 2019
- Fundamental
- Price
- LFWD $0.68
- NXTC $0.44
- Analyst Decision
- LFWD Strong Buy
- NXTC Strong Buy
- Analyst Count
- LFWD 3
- NXTC 2
- Target Price
- LFWD $9.00
- NXTC $3.50
- AVG Volume (30 Days)
- LFWD 1.4M
- NXTC 357.7K
- Earning Date
- LFWD 08-14-2025
- NXTC 07-31-2025
- Dividend Yield
- LFWD N/A
- NXTC N/A
- EPS Growth
- LFWD N/A
- NXTC N/A
- EPS
- LFWD N/A
- NXTC N/A
- Revenue
- LFWD $25,414,000.00
- NXTC N/A
- Revenue This Year
- LFWD $12.04
- NXTC N/A
- Revenue Next Year
- LFWD $40.58
- NXTC N/A
- P/E Ratio
- LFWD N/A
- NXTC N/A
- Revenue Growth
- LFWD 41.92
- NXTC N/A
- 52 Week Low
- LFWD $0.50
- NXTC $0.22
- 52 Week High
- LFWD $4.77
- NXTC $1.82
- Technical
- Relative Strength Index (RSI)
- LFWD 26.18
- NXTC 42.34
- Support Level
- LFWD $0.60
- NXTC $0.45
- Resistance Level
- LFWD $0.73
- NXTC $0.49
- Average True Range (ATR)
- LFWD 0.09
- NXTC 0.06
- MACD
- LFWD -0.03
- NXTC -0.01
- Stochastic Oscillator
- LFWD 25.26
- NXTC 4.72
About LFWD REWALK ROBOTICS LTD
Lifeward Ltd is a medical device company that designs, develops, and commercializes life-changing solutions that span the continuum of care in physical rehabilitation and recovery, delivering functional and health benefits in clinical settings as well as in the home and community. Its product offerings are the ReWalk Exoskeleton, the ReStore Exo-Suit, the MyoCycle FES bikes, and AlterG Anti-Gravity systems. It operates through markets in the United States, Israel, and Germany.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.